Revvity (PKN) Stock Overview
Provides health sciences solutions, technologies, and services. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
PKN Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Revvity, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$105.05 |
| 52 Week High | US$113.10 |
| 52 Week Low | US$83.30 |
| Beta | 1.09 |
| 1 Month Change | 5.22% |
| 3 Month Change | 21.81% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 661.23% |
Recent News & Updates
Recent updates
Shareholder Returns
| PKN | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | -5.9% | -4.4% | -2.1% |
| 1Y | n/a | 9.5% | 3.6% |
Return vs Industry: Insufficient data to determine how PKN performed against the German Life Sciences industry.
Return vs Market: Insufficient data to determine how PKN performed against the German Market.
Price Volatility
| PKN volatility | |
|---|---|
| PKN Average Weekly Movement | 5.7% |
| Life Sciences Industry Average Movement | 6.7% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in DE Market | 12.6% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: PKN has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine PKN's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1937 | 11,000 | Prahlad Singh | www.revvity.com |
Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions.
Revvity, Inc. Fundamentals Summary
| PKN fundamental statistics | |
|---|---|
| Market cap | €11.90b |
| Earnings (TTM) | €204.42m |
| Revenue (TTM) | €2.51b |
Is PKN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PKN income statement (TTM) | |
|---|---|
| Revenue | US$2.91b |
| Cost of Revenue | US$1.31b |
| Gross Profit | US$1.60b |
| Other Expenses | US$1.36b |
| Earnings | US$237.37m |
Last Reported Earnings
Jul 05, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.13 |
| Gross Margin | 54.98% |
| Net Profit Margin | 8.15% |
| Debt/Equity Ratio | 44.3% |
How did PKN perform over the long term?
See historical performance and comparisonDividends
Does PKN pay a reliable dividends?
See PKN dividend history and benchmarks| Revvity dividend dates | |
|---|---|
| Ex Dividend Date | Oct 23 2026 |
| Dividend Pay Date | Nov 13 2026 |
| Days until Ex dividend | 41 days |
| Days until Dividend pay date | 62 days |
Does PKN pay a reliable dividends?
See PKN dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/10 15:57 |
| End of Day Share Price | 2026/09/10 00:00 |
| Earnings | 2026/07/05 |
| Annual Earnings | 2025/12/28 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Revvity, Inc. is covered by 40 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Robert Bamberger | Baird |
| Luke Sergott | Barclays |